{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:39:00Z","timestamp":1761514740018,"version":"3.41.2"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1136\/ijgc-2021-002380","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T12:15:26Z","timestamp":1616156126000},"page":"694-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct03469674","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01244789","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04214067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01244789","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01244789","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04214067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04214067","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-4561","authenticated-orcid":false,"given":"Leonid B","family":"Reshko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy T","family":"Gaskins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M","family":"Dryden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S","family":"Metzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet B","family":"Eldredge-Hindy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-002380_bb0010","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2021-002380_bb0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.2004.08.159","article-title":"Outcome of high-risk stage Ic, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial","volume":"22","author":"Creutzberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0020","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ijrobp.2005.03.007","article-title":"Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review","volume":"63","author":"Scholten","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"journal-title":"Uterine Neoplasms. NCCN Guidelines Version 2.2021 - October 28, 2020","year":"2021","author":"Abu-Rustum","key":"10.1136\/ijgc-2021-002380_bb0025"},{"key":"10.1136\/ijgc-2021-002380_bb0030","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0035","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.ijrobp.2011.04.014","article-title":"External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma-a prospective randomized study","volume":"82","author":"Sorbe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2021-002380_bb0040","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0045","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","article-title":"Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study","volume":"108","author":"Susumu","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0050","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2021-002380_bb0055","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.19.00037","article-title":"Uterine cancer: adjuvant therapy and management of metastatic disease","volume":"37","author":"Creutzberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0060","first-page":"419","article-title":"Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients","volume":"56","author":"Aalders","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2021-002380_bb0065","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in High-Intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2016.11.003","article-title":"Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort","volume":"144","author":"Wong","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0075","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/IGC.0000000000000963","article-title":"The addition of adjuvant chemotherapy to radiation in early-stage high-risk endometrial cancer: survival outcomes and patterns of care","volume":"27","author":"Boothe","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002380_bb0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ygyno.2017.01.024","article-title":"Disparities in receipt of care for high-grade endometrial cancer: a national cancer data base analysis","volume":"145","author":"Bregar","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0085","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.radonc.2016.12.003","article-title":"Improved overall survival with adjuvant radiotherapy for high-intermediate and high risk stage I endometrial cancer","volume":"122","author":"Harkenrider","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0090","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1002\/cncr.30228","article-title":"Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: a national cancer data base study","volume":"122","author":"Rydzewski","year":"2016","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2021-002380_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-019-1620-x","article-title":"Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma","volume":"17","author":"Veade","year":"2019","journal-title":"World J Surg Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2016.10.028","article-title":"Adjuvant radiation therapy is associated with improved overall survival in high-intermediate risk stage I endometrial cancer: a national cancer data base analysis","volume":"144","author":"Gupta","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0105","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e39","article-title":"Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma","volume":"31","author":"Xiang","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0110","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2021-002380_bb0115","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COC.0000000000000273","article-title":"Stage I and II endometrial adenocarcinoma: analysis of 2009 FIGO staging revision and impact on survival by adjuvant therapy","volume":"41","author":"Cahan","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2019.12.028","article-title":"Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: is there a role for chemotherapy?","volume":"156","author":"Beavis","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jso.23568","article-title":"Comparing national cancer registries: the National Cancer Data Base (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program","volume":"109","author":"Mohanty","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1471-0528.1989.tb03341.x","article-title":"Revised FIGO staging for gynaecological cancer","volume":"96","author":"Shepherd","year":"1989","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1136\/ijgc-2021-002380_bb0135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1136\/ijgc-2021-002380_bb0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","article-title":"Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study","volume":"40","author":"Morrow","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0145","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the national cancer database for outcomes research: a review","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2021-002380_bb0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2021-002380_bb0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2018.07.020","article-title":"Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial","volume":"151","author":"Wortman","year":"2018","journal-title":"Gynecol Oncol"},{"journal-title":"Chemotherapy or observation in stage I-II intermediate or high risk endometrial cancer. ClinicalTrials.gov Identifier: [Internet] Copenhagen","year":"2018","author":"Group DGC","key":"10.1136\/ijgc-2021-002380_bb0160"},{"journal-title":"Testing the addition of the immunotherapy drug, pembrolizumab, to the usual radiation treatment for newly diagnosed early stage high intermediate risk endometrial cancer: [Internet]. National Cancer Institute (NCI): NRG Oncology","year":"2019","author":"Backes","key":"10.1136\/ijgc-2021-002380_bb0165"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2402334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2402334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-002380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:26:44Z","timestamp":1753234004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2402334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1048891X2402334X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-002380","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-002380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}